LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Assay Determines Suitability of Nanoparticles for In Vivo Use

By LabMedica International staff writers
Posted on 28 Feb 2017
Image: Macrophages with ingested nanoparticles (green) (Photo courtesy of the Bourquin Laboratory, University of Geneva).
Image: Macrophages with ingested nanoparticles (green) (Photo courtesy of the Bourquin Laboratory, University of Geneva).
A team of Swiss researchers has developed a flow cytometry-based test to determine whether specific types of nanoparticles are suitable for use in humans or animals.

Nanoparticles as carriers of drugs, genetic material, or other substances of biomedical interest are under investigation in many laboratories. However, their interaction with immune cells has been difficult to predict. Macrophages are among the first type of cells that take up nanoparticles, mediating inflammation and thus immunological responses. A recent study described a highly reproducible screening method to study the interaction of nanoparticles with macrophages.

Investigators at the University of Geneva and the University of Fribourg reported in the February 2, 2017, online edition of the journal Nanoscale that they had developed a flow cytometry-based assay that could determine for a single nanoparticle sample whether the nanoparticles were taken up by macrophages, whether the nanoparticles caused death of the macrophages, and whether the nanoparticles triggered an inflammatory immune response.

To perform the assay, macrophages were brought into contact with the nanoparticles for 24 hours, and were then evaluated in a flow cytometer. The fluorescence emitted by the macrophages made it possible to count them and characterize their activation levels. Since the particles themselves were fluorescent, the investigators could also measure the amount of particles ingested by the macrophages. Thus, the three elements could be determined simultaneously in two or three days on a very small amount of particles.

"Researchers can spend years developing a nanoparticle, without knowing what impact it will have on a living organism," said senior author Dr. Carole Bourquin, professor of medicine at the University of Geneva. "So there was a real need to design an effective screening method that could be implemented at the beginning of the development process. Indeed, if the nanoparticles aren’t compatible, several years of research were simply thrown away."

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Sample Transportation System
Tempus1800 Necto

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more